Johnson & Johnson (NYSE:JNJ) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 323,830 shares of the company’s stock after acquiring an additional 10,387 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Johnson & Johnson were worth $46,827,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Leigh Baldwin & CO. LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $135,043,000. Logan Capital Management Inc. grew its position in shares of Johnson & Johnson by 2.6% during the fourth quarter. Logan Capital Management Inc. now owns 48,336 shares of the company’s stock worth $6,990,000 after acquiring an additional 1,214 shares during the last quarter. LRI Investments LLC grew its position in shares of Johnson & Johnson by 2.5% during the fourth quarter. LRI Investments LLC now owns 12,753 shares of the company’s stock worth $1,844,000 after acquiring an additional 311 shares during the last quarter. Laraway Financial Advisors Inc grew its position in Johnson & Johnson by 7.4% in the 4th quarter. Laraway Financial Advisors Inc now owns 5,141 shares of the company’s stock valued at $744,000 after buying an additional 354 shares in the last quarter. Finally, Investor s Fiduciary Advisor Network LLC bought a new position in Johnson & Johnson in the 4th quarter valued at about $984,000. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00% decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Bank of America decreased their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 16th. Finally, Raymond James decreased their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. Ten investment analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Price Performance

JNJ stock opened at $148.71 on Wednesday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The firm has a market capitalization of $357.81 billion, a PE ratio of 22.36, a P/E/G ratio of 2.56 and a beta of 0.42. The firm has a 50-day moving average of $157.33 and a two-hundred day moving average of $154.14.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a $1.30 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.50%. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.